Blinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden
Authors:
- Paweł MarschollekPMPaweł Marschollek
- Karolina LiszkaKLKarolina Liszka
- Monika Mielcarek-SiedziukMMMonika Mielcarek-Siedziuk
- Blanka RybkaBRBlanka Rybka
- Renata Ryczan-KrawczykRRRenata Ryczan-Krawczyk
- Anna PanasiukAPAnna Panasiuk
- Igor OlejnikIOIgor Olejnik
- Jowita FrączkiewiczJFJowita Frączkiewicz
- Iwona Dachowska-KałwakIDIwona Dachowska-Kałwak
- Agnieszka Mizia-MalarzAMAgnieszka Mizia-Malarz
- Tomasz SzczepańskiTSTomasz Szczepański
- Wojciech MłynarskiWMWojciech Młynarski
Open Access
- 13 November 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2915
Abstract
The optimal bridging therapy before CAR-T cell infusion in pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL) still remains an open question. The administration of blinatumomab prior to CAR-T therapy is controversial since a potential loss of CD19+ target cells may negatively impact the activation, persistence, and, as a consequence, the efficacy of subsequently used CAR-T cells. Here, we report a single-center experience in seven children with chemorefractory BCP-ALL treated with blinatumomab before CAR-T cell therapy either to reduce disease burden before apheresis (six patients) or as a bridging therapy (two patients). All patients responded to blinatumomab except one. At the time of CAR-T cell infusion, all patients were in cytological complete remission (CR). Four patients had low positive PCR-MRD, and the remaining three were MRD-negative. All patients remained in CR at day +28 after CAR-T infusion, and six out of seven patients were MRD-negative. With a median follow-up of 497 days, four patients remain in CR and MRD-negative. Three children relapsed with CD19 negative disease: two of them died, and one, who previously did not respond to blinatumomab, was successfully rescued by stem cell transplant. To conclude, blinatumomab can effectively lower disease burden with fewer side effects than standard chemotherapeutics. Therefore, it may be a valid option for patients with high-disease burden prior to CAR-T cell therapy without clear evidence of compromising efficacy; however, further investigations are necessary.Keywords
Funding Information
- Wroclaw Medical University
This publication has 25 references indexed in Scilit:
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Tumor Antigen Escape from CAR T-cell TherapyCancer Discovery, 2018
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucelJournal of Hematology & Oncology, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatmentBlood Cancer Journal, 2017
- Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter StudyJournal of Clinical Oncology, 2017
- Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2016
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapyBlood, 2016
- Catch me if you can: Leukemia Escape after CD19-Directed T Cell ImmunotherapiesComputational and Structural Biotechnology Journal, 2016
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 ImmunotherapyCancer Discovery, 2015